relapsing multiple sclerosis

FDA Delays Ruling on Novartis’ Relapsing Multiple Sclerosis Drug
FDA Delays Ruling on Novartis’ Relapsing Multiple Sclerosis Drug
BioSpace
Novartis
Arzerra
FDA
ofatumumab
relapsing multiple sclerosis
Flag link:
Janssen’s MS pill outshines Sanofi’s Aubagio in phase 3 trial
Janssen’s MS pill outshines Sanofi’s Aubagio in phase 3 trial
Pharmaforum
JNJ
Janssen
ponesimod
Sanofi
Aubagio
relapsing multiple sclerosis
Flag link:
Novartis’ ofatumumab meets primary endpoints in two phase 3 RMS trials
Novartis’ ofatumumab meets primary endpoints in two phase 3 RMS trials
Pharmaceutical Business Review
Novartis
ofatumumab
OMB157
Aubagio
clinical trials
relapsing multiple sclerosis
Flag link:
Janssen’s Ponesimod Finds Success in Head-to-Head Multiple Sclerosis Trial
Janssen’s Ponesimod Finds Success in Head-to-Head Multiple Sclerosis Trial
BioSpace
Janssen
JNJ
ponesimod
Sanofi
Aubagio
relapsing multiple sclerosis
Flag link:
3 Drugs Under FDA Review With Blockbuster Potential
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Flag link:
FDA approves Novartis' Mayzent for MS
FDA approves Novartis' Mayzent for MS
BioCentury
FDA
Novartis
Mayzent
siponimod
relapsing multiple sclerosis
Flag link:
Roche unveils long-term data from MS blockbuster Ocrevus
Roche unveils long-term data from MS blockbuster Ocrevus
Pharmaforum
Roche
Ocrevus
relapsing multiple sclerosis
MS
Flag link:
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
CP Wire
Celgene
ozanimod
relapsing multiple sclerosis
MS
Flag link: